ClinicalTrials.gg
Not yet recruitingNCT07412236Updated Feb 17, 2026

A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.

A Phase 3 interventional study of Hydronidone (270mg) and Hydronidone (Placebo Group) in Liver Fibrosis and Liver Fibrosis in Chronic Hepatitis B, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,208
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 214 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.

Planned enrollment
4th of 127
1,208 · median 120
Started
2026
with 19 others
Phase 3
9 of 214
4 open now
Primary completion
2028-12
later than 60 of 72 live
Registered
192nd of 214
by date
Lead sponsor
6 of 214
Beijing Continent Pharmaceutical Co, Ltd.

Among the 214 studies in Liver Cirrhosis with a site in China, this one is the 4th largest by planned enrollment of the 127 interventional ones that give a count, is one of 20 that started in 2026, is one of 9 in phase 3, reaches primary completion later than 60 of the 72 other live ones, and was the 192nd registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

65 of the 214 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

This study is conducted as a randomized, double-blind, placebo-controlled, multicenter clinical trial on a background of entecavir therapy. It aims to evaluate the clinical benefits of Hydronidone Capsules in patients with liver fibrosis due to chronic hepatitis B. The study consists of a Screening/Baseline Period (4 weeks) and a Dosing/Observation Period (planned duration of 5 years, including a 52-week primary treatment phase and a 208-week long-term treatment phase).

03

Conditions studied

  • Liver Fibrosis
  • Liver Fibrosis in Chronic Hepatitis B

Browse trials for

Keywords

  • LIver Fibrosis in Chronic Hepatitis B
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years (inclusive of 18 and 65 years old at the time of signing the form), male or female;
  • Documented history of chronic and/or positive for hepatitis B surface antigen (HBsAg) for ≥6 months;
  • Treatment-naïve or treatment-experienced patients with chronic hepatitis B, defined as follows:

    1. Treatment-naïve patients must meet all of the following criteria:

      • No prior systemic antiviral therapy (e.g., interferon and/or nucleos(t)ide analogues) before randomization;
      • Positive for HBV DNA;
      • Liver stiffness measurement (LSM) by transient elastography ≥12.4 kPa for treatment-naïve patients with >2 × ; or LSM ≥10.6 kPa for treatment-naïve patients with ALT ≤2 × ULN. Subjects whose LSM does not meet the above criteria may still be enrolled if they have liver evidence (within the past 6 months) confirming liver fibrosis of Ishak score ≥3.
    2. Treatment-experienced patients must meet all of the following criteria:

      • A history of ≥6 months of continuous nucleos(t)ide analogue therapy for hepatitis B up to randomization, currently receiving monotherapy with a nucleos(t)ide analogue [e.g., Tenofovir Alafenamide Fumarate (TAF), Tenofovir Disoproxil Fumarate (TDF), or Entecavir (ETV)];
      • HBV DNA positive or negative is acceptable;
      • Liver stiffness measurement (LSM) by transient elastography >9.0 kPa. Subjects whose LSM does not meet the above criteria may still be enrolled if they have liver biopsy evidence (within the past 6 months) confirming liver fibrosis of Ishak score ≥3.
  • ALT \<8 × ULN;
  • No use within 3 months prior to randomization of the following Chinese patent medicines that may have antifibrotic effects: Fuzhenghuayu Capsule (Tablet), Anluohuaxian Pill, Compound Biejia Ruangan Tablet, etc.;
  • Subjects (or their sexual partners) have no pregnancy plan during the trial and for 6 months after trial completion, voluntarily agree to use effective physical methods, and have no plan to donate sperm or eggs;
  • Subjects have fully understood the nature, significance, potential benefits, possible inconveniences, and potential risks of the trial prior to participation, voluntarily agree to take part in this clinical trial, are able to communicate well with the investigators, agree to comply with all study requirements, and have provided written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Total (TBil) >3 × , or 3 × ULN \< \<8 × ULN with TBil >2 × ULN;
  • count (PLT) ≤50 × 10⁹/L;
  • Prothrombin activity (PTA) \<50% or (INR) >1.5;
  • Imaging findings suggestive of a space-occupying lesion in the liver indicative of tumor, or alpha-fetoprotein (AFP) >100 μg/L even in the absence of specific signs of hepatocellular carcinoma;
  • Patients with decompensated liver cirrhosis (complications including ascites, esophageal and/or gastric variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatopulmonary syndrome, hepatic encephalopathy, portal vein thrombosis, and cirrhotic cardiomyopathy) or with hepatic ;
  • Patients with chronic or non-viral chronic hepatitis (alcoholic, drug-induced, etc., excluding metabolic dysfunction-associated steatotic liver disease (MASLD));
  • History of alcohol abuse or inability to abstain from alcohol recently [Note: Alcohol abuse is defined as: ① daily ethanol consumption ≥40 g for males or ≥20 g for females for 5 consecutive years; OR ② history of heavy alcohol consumption (>80 g of ethanol per day) within the past 2 weeks. Ethanol (g) = volume of alcoholic beverage consumed (mL) × alcohol by volume (%) × 0.8];
  • Patients with severe concurrent cardiovascular, pulmonary, renal, endocrine, neurological, or hematological diseases, or psychiatric disorders;
  • Pregnant and/or lactating women;
  • Participation in any other drug clinical trial within the past 3 months;
  • Any condition that, in the investigator's judgment, may affect the subject's ability to provide or comply with the trial protocol, or participation that may affect the trial results or the subject's own safety.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,208 participants (estimated)

Study arms

  • Experimental
    Hydronidone Capsule Group (270 mg)

    Treatment Group

    Drug: Hydronidone (270mg)

  • Placebo comparator
    Hydronidone Capsule Group (Placebo Group)

    Placebo Group

    Drug: Hydronidone (Placebo Group)

Interventions

  • Dosage: 30 mg/capsule, three capsules taken three times daily, resulting in a total daily therapeutic dose of 270 mg. The medication is administered orally half an hour before meals.

  • DrugHydronidone (Placebo Group)

    Dosage: three capsules taken three times daily.The medication is administered orally half an hour before meals.

06

What researchers measure

Primary outcomes

  1. Incidence of Clinical Endpoint Events

    The clinical endpoint event is a composite event, which includes progression to complications of decompensated cirrhosis (such as ascites, esophageal and gastric variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatopulmonary syndrome, hepatic encephalopathy, portal vein thrombosis, and cirrhotic cardiomyopathy, etc.), hepatocellular carcinoma, liver transplantation, and liver disease-related death/all-cause death. The time of event occurrence is determined by whichever occurs first, and the occurrence of any of these events constitutes a clinical endpoint event.

    Time frame: From the first dose administration to the end of the treatment period (Week 261).

Secondary outcomes

  1. Annualized Incidence Rate of Clinical Endpoint Events

    Time frame: From the first dose administration to the end of the treatment period (Week 261).

  2. The incidence rates of individual components of the clinical endpoint events

    Time frame: From the first dose administration to the end of the treatment period (Week 261).

  3. The annualized incidence rates of individual components of the clinical endpoint events

    Time frame: From the first dose administration to the end of the treatment period (Week 261).

  4. Change from baseline in liver stiffness measurement (LSM) by transient elastography (kPa) after treatment.

    Time frame: From the first dose administration to the end of the treatment period (Week 261).

  5. Undetectable rate of Hepatitis B virus deoxyribonucleic acid (HBV DNA) after treatment (below the lower limit of detection).

    Time frame: From the first dose administration to the end of the treatment period (Week 261).

  6. Magnitude of reduction in Hepatitis B virus deoxyribonucleic acid (HBV DNA) after treatment.

    Time frame: From the first dose administration to the end of the treatment period (Week 261).

  7. Magnitude of improvement in alanine aminotransferase (ALT) levels after treatment.

    Time frame: From the first dose administration to the end of the treatment period (Week 261).

  8. Normalization rate of improvement in alanine aminotransferase (ALT) levels after treatment.

    Time frame: From the first dose administration to the end of the treatment period (Week 261).

  9. Normalization rate of improvement in aspartate aminotransferase (AST) levels after treatment.

    Time frame: From the first dose administration to the end of the treatment period (Week 261).

  10. Magnitude of improvement in aspartate aminotransferase (AST) levels after treatment.

    Time frame: From the first dose administration to the end of the treatment period (Week 261).

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2028, 35 months later.

Of 25 phase 3 interventional studies under Liver Cirrhosis, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 82. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 17, 2026
StartEst.
Jan 30, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07412236
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Jan 30, 2026 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Feb 17, 2026

Study contacts

Ling Zhang
Contact
zhangling@bjcontinent.com
+86-13501209210

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydronidone

Start the discussion